Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12497396 | 0.91 | APP (0.65) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12684795 | 0.91 | APP (0.68) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL7938312 | 0.90 | APP (0.64) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL1844567 | 0.90 | APP (0.64) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12497236 | 0.89 | APP (0.66) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12684717 | 0.88 | APP (0.64) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL1844781 | 0.88 | APP (0.61) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12497115 | 0.87 | APP (0.63) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12684715 | 0.86 | APP (0.62) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12684738 | 0.86 | APP (0.62) | APPHTR6MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160283652-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160283652-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-20140187556-A1 | ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187556-A1 | ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2320897-B1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2012119035-A1 | ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | APP 3/4885HTR6 1377/4885MAPT 10/4885 |
| US-20140187556-A1 | ANTI-AMYLOID COMPOUNDS AND METHODS | APP, BACE1, PRNP | APP 1/4885HTR6 2161/4885MAPT 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.